Multiple preclinical studies strengthened VISTA’s candidacy as an immune‑checkpoint target. One paper shows that loss of TRIM25 enhances anti‑tumor immunity by modulating VISTA pathways in T cells; complementary work demonstrates that direct VISTA blockade augments anti‑tumor responses in models that are resistant to PD‑1/PD‑L1 therapy. Together the findings provide mechanistic rationale for companies and academic groups to prioritize VISTA inhibitors or combination regimens. The studies name specific molecular actors and suggest new biomarker strategies to select patients for VISTA‑directed approaches.